Alps Advisors Inc Rhythm Pharmaceuticals, Inc. Transaction History

Alps Advisors Inc

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$39.12 - $52.44 $86,220 - $115,577	2,204 Added 5.48%	42,419 $1.84 Million
Q4 2023 Feb 14, 2024	SELL	$21.39 - $49.64 $37,133 - $86,175	-1,736 Reduced 4.14%	40,215 $1.85 Million
Q3 2023 Nov 14, 2023	BUY	$15.81 - $27.8 $2,497 - $4,392	158 Added 0.38%	41,951 $961,000
Q2 2023 Aug 14, 2023	BUY	$16.32 - $21.15 $71,889 - $93,165	4,405 Added 11.78%	41,793 $689,000
Q1 2023 May 10, 2023	SELL	$16.88 - $34.24 $13,672 - $27,734	-810 Reduced 2.12%	37,388 $667,000
Q4 2022 Feb 14, 2023	BUY	$22.21 - $30.25 $848,377 - $1.16 Million	38,198 New	38,198 $1.11 Million
Q4 2019 Feb 07, 2020	SELL	$19.53 - $25.5 $1.34 Million - $1.76 Million	-68,850 Closed	0 $0
Q3 2019 Nov 04, 2019	SELL	$18.62 - $24.51 $59,956 - $78,922	-3,220 Reduced 4.47%	68,850 $1.49 Million
Q2 2019 Aug 07, 2019	SELL	$21.11 - $28.48 $233,159 - $314,561	-11,045 Reduced 13.29%	72,070 $1.59 Million
Q1 2019 May 01, 2019	BUY	$24.76 - $31.66 $88,987 - $113,786	3,594 Added 4.52%	83,115 $2.28 Million
Q4 2018 Feb 04, 2019	BUY	$24.11 - $31.34 $459,174 - $596,870	19,045 Added 31.49%	79,521 $2.14 Million
Q3 2018 Oct 25, 2018	BUY	$26.99 - $35.85 $553,942 - $735,785	20,524 Added 51.37%	60,476 $1.76 Million
Q2 2018 Aug 02, 2018	BUY	$17.02 - $35.2 $188,241 - $389,312	11,060 Added 38.28%	39,952 $1.25 Million
Q2 2018 Jul 25, 2018	SELL	$17.02 - $35.2 $131,071 - $271,075	-7,701 Reduced 21.05%	28,892 $840,000
Q1 2018 May 01, 2018	BUY	$19.9 - $32.25 $728,200 - $1.18 Million	36,593 New	36,593 $728,000

191

67.3M

834K

78.6K

Ticker RYTM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,720,000
Market Cap $3.13B
Description
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convert...

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

Stay updated on Alps Advisors Inc with notifications on news.